Cardiff Oncology (CRDF) Enterprise Value (2011 - 2026)

Cardiff Oncology has reported Enterprise Value for 15 years, with the latest figure at -$58.3 million in Q4 2025.

• Quarterly Enterprise Value rose 36.45% year-over-year to -$58.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$58.3 million (up 36.45% YoY) and the FY2025 annual result came in at -$58.3 million, up 36.45% from the prior year.
• Enterprise Value improved to -$58.3 million in Q4 2025 per CRDF's latest filing, from -$60.6 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$57.7 million in Q3 2024 and troughed at -$140.8 million in Q4 2021.
• A 5-year average of -$95.0 million and a median of -$90.6 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2021 and 2025: Enterprise Value slumped 1253.71% in 2021, then jumped 36.45% in 2025.
• Over 5 years, Enterprise Value stood at -$140.8 million in 2021, then climbed by 25.25% to -$105.3 million in 2022, then increased by 28.92% to -$74.8 million in 2023, then fell by 22.62% to -$91.7 million in 2024, then surged by 36.45% to -$58.3 million in 2025.
• According to Business Quant data, Enterprise Value over the past three periods registered -$58.3 million, -$60.6 million, and -$71.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.